FINRA seeks to delay some of VA sales rule

The regulator wants to delay a rule that governs the review of deferred variable annuity sales.
APR 18, 2008
The Financial Industry Regulatory Authority Inc. has proposed to delay the principal-review portion of Rule 2821, a rule that governs the review of deferred variable annuity sales. The New York and Washington-based regulator yesterday announced that it will file with the Securities and Exchange Commission to push back the effective date for principal review and supervisory/compliance procedures for 180 days after Finra files a rule change. As part of Section C of the rule, principals at Finra member firms would review the suitability of the annuity applications within seven business days of the customer’s signing the application, prior to sending the application to the insurance carrier. However, firms argued that this wouldn’t be enough time for a thorough review, and requested that Finra consider a different timing mechanism. Other firms wondered how the rule would apply to broker-dealers who don’t make investment recommendations and who therefore don’t have principals to check suitability. Last fall, this portion of the rule was pushed back to Aug. 4 to allow firms extra time to prepare. Section D, governing supervisory and compliance procedures, also has been delayed. Sections A, B and E, which focus on training registered reps and adhering to suitability standards, are still scheduled to go into effect May 5.

Latest News

Retiree alleges advisor withheld $600K through real estate LLC web
Retiree alleges advisor withheld $600K through real estate LLC web

$1.7M invested from an inheritance. Then the phone went dead.

SEC accuses Linqto chiefs of 'Wizard of Oz' investor deception
SEC accuses Linqto chiefs of 'Wizard of Oz' investor deception

The pre-IPO platform sold $430M in units while allegedly rigging prices behind the scenes.

GLP-1 users are trading retirement savings for their prescriptions
GLP-1 users are trading retirement savings for their prescriptions

A Nationwide survey finds 47% of GLP-1 users have never discussed the drugs’ financial impact with an advisor, even as many dip into savings.

Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors
Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors

The hundreds of millions of dollars from a sale of Inspired Healthcare properties does not mean an immediate windfall for investors.

Class action alleges Webull misled investors about China operations
Class action alleges Webull misled investors about China operations

Its SEC filings said one thing - a congressional probe said another.

SPONSORED Built on insurance experience to deliver on long-term promises

Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.

SPONSORED In the Age of AI, Trust Becomes the Advisor's Greatest Asset

As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor